ARK Invest Increases Stake in AeroVironment
ARK Invest purchased 59,171 shares of AeroVironment, Inc. (AVAV) on October 27, 2026, for approximately $7.29 million.
Stocks · News reference
Wealthfront, Orchestra Biomed, AeroVironment And Other Big Stocks Moving Higher On Thursday
U.S. stocks fell, but Wealthfront surged 6.6% after beating Q2 earnings and revenue estimates; Orchestra Biomed, Clover Health and AeroVironment also rose.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Oppenheimer Initiates AeroVironment at Outperform With $205 Price Target
Oppenheimer has initiated coverage on AeroVironment, Inc. with an 'Outperform' rating and a price target of $205 per share.
DPRO Expands Defense Autonomy Capabilities Through Strategic Investment
Draganfly (DPRO) announced a strategic investment in DoD Solution, an Estonian-Ukrainian defense technology company, to expand its drone autonomy capabilities. The investment provides access to AURA AI technology for autonomous navigation, target tracking, and guidance in GPS-denied environments. Successful integration could strengthen Draganfly's competitive positioning in the defense market and create opportunities for longer-term growth and commercial agreements.
Citizens Maintains Market Outperform on AeroVironment, Lowers Price Target to $170
Citizens analyst Trevor Walsh maintains AeroVironment (NASDAQ:AVAV) with a Market Outperform and lowers the price target from $230 to $170.
Needham Initiates Coverage of Clover Health Investments with Buy Rating
Needham & Company has initiated research coverage on Clover Health Investments, Corp. with a 'Buy' rating and a price target of $6.00.
Clover Health to Participate in Upcoming UBS Global Healthcare Conference
Clover Health Investments, Corp. announced that its Interim Chief Financial Officer, Clay Thornton, will present at the 2026 UBS Global Healthcare Conference on November 9, 2026.